These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11437953)

  • 21. [Estimation of the binding site of drugs by means of new types of photoactive ligands].
    Dormán G
    Acta Pharm Hung; 1998 Mar; 68(2):95-105. PubMed ID: 9592934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of a thrombin receptor tethered ligand analogue to human platelet thrombin receptor.
    Ahn HS; Foster C; Boykow G; Arik L; Smith-Torhan A; Hesk D; Chatterjee M
    Mol Pharmacol; 1997 Feb; 51(2):350-6. PubMed ID: 9203642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells.
    Hwa JJ; Ghibaudi L; Williams P; Chintala M; Zhang R; Chatterjee M; Sybertz E
    Circ Res; 1996 Apr; 78(4):581-8. PubMed ID: 8635215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets.
    Henriksen RA; Hanks VK
    Arterioscler Thromb Vasc Biol; 2002 May; 22(5):861-6. PubMed ID: 12006403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor-activating peptides distinguish thrombin receptor (PAR-1) and protease activated receptor 2 (PAR-2) mediated hemodynamic responses in vivo.
    Cheung WM; Andrade-Gordon P; Derian CK; Damiano BP
    Can J Physiol Pharmacol; 1998 Jan; 76(1):16-25. PubMed ID: 9564545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological characterization of protease-activated receptor (PAR-1) in rat astrocytes.
    Debeir T; Vigé X; Benavides J
    Eur J Pharmacol; 1997 Mar; 323(1):111-7. PubMed ID: 9105886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist.
    Ahn HS; Foster C; Boykow G; Stamford A; Manna M; Graziano M
    Biochem Pharmacol; 2000 Nov; 60(10):1425-34. PubMed ID: 11020444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of thrombin and the thrombin receptor activating peptide, SFLLRN, on redistribution of platelet alpha-granule contents are similar and independent of the extent of thromboxane formation.
    Suzuki H; Packham MA; Kinlough-Rathbone RL
    Exp Mol Pathol; 1995 Feb; 62(1):63-72. PubMed ID: 7556592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide.
    Blackhart BD; Ruslim-Litrus L; Lu CC; Alves VL; Teng W; Scarborough RM; Reynolds EE; Oksenberg D
    Mol Pharmacol; 2000 Dec; 58(6):1178-87. PubMed ID: 11093752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different abilities of thrombin receptor activating peptide and thrombin to induce platelet calcium rise and full release reaction.
    Lasne D; Donato J; Falet H; Rendu F
    Thromb Haemost; 1995 Nov; 74(5):1323-8. PubMed ID: 8607117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of action of proteinase-activated receptor agonists on human platelets.
    Chung AW; Jurasz P; Hollenberg MD; Radomski MW
    Br J Pharmacol; 2002 Mar; 135(5):1123-32. PubMed ID: 11877318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor binding and agonist efficacy: new insights from mutants of the thrombin protease-activated receptor-1 (PAR-1).
    Hollenberg MD
    Mol Pharmacol; 2000 Dec; 58(6):1175-7. PubMed ID: 11093751
    [No Abstract]   [Full Text] [Related]  

  • 33. Differential roles of two consecutive phenylalanine residues in thrombin receptor-tethered ligand peptides (SFFLRNP) in thrombin receptor activation.
    Shimohigashi Y; Nose T; Okazaki M; Satoh Y; Ohno M; Costa T; Shimizu N; Ogino Y
    Biochem Biophys Res Commun; 1994 Aug; 203(1):366-72. PubMed ID: 8074680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A trypsin-like platelet protease propagates protease-activated receptor-1 cleavage and platelet activation.
    Ofosu FA; Freedman J; Dewar L; Song Y; Fenton JW
    Biochem J; 1998 Dec; 336 ( Pt 2)(Pt 2):283-5. PubMed ID: 9820801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
    Dong M; Liu G; Pinon DI; Miller LJ
    Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Essential groups in synthetic agonist peptides for activation of the platelet thrombin receptor.
    Chao BH; Kalkunte S; Maraganore JM; Stone SR
    Biochemistry; 1992 Jul; 31(27):6175-8. PubMed ID: 1320929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN.
    Dupont A; Fontana P; Bachelot-Loza C; Reny JL; Biéche I; Desvard F; Aiach M; Gaussem P
    Blood; 2003 Mar; 101(5):1833-40. PubMed ID: 12406873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
    Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
    Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN.
    Rand ML; Sangrar W; Hancock MA; Taylor DM; Marcovina SM; Packham MA; Koschinsky ML
    Arterioscler Thromb Vasc Biol; 1998 Sep; 18(9):1393-9. PubMed ID: 9743227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences between platelet phosphoinositide metabolism stimulated by thrombin or SFLLRN are not accounted for by interaction of thrombin with glycoprotein Ib.
    Vickers JD; Packham MA; Kinlough-Rathbone RL
    Am J Hematol; 1997 Apr; 54(4):288-95. PubMed ID: 9092683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.